| Confronting the stigma of opioid use disorder—and its treatment Y Olsen, JM Sharfstein Jama 311 (14), 1393-1394, 2014 | 413 | 2014 |
| Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009 RP Schwartz, J Gryczynski, KE O’grady, JM Sharfstein, G Warren, Y Olsen, ... American journal of public health 103 (5), 917-922, 2013 | 358 | 2013 |
| Diagnostic testing for the novel coronavirus JM Sharfstein, SJ Becker, MM Mello Jama 323 (15), 1437-1438, 2020 | 270 | 2020 |
| A systemic approach to containing health care spending E Emanuel, N Tanden, S Altman, S Armstrong, D Berwick, F De Brantes, ... New England Journal of Medicine 367 (10), 949-954, 2012 | 223 | 2012 |
| A bold response to the COVID-19 pandemic: medical students, national service, and public health H Bauchner, J Sharfstein Jama 323 (18), 1790-1791, 2020 | 194 | 2020 |
| Regulatory action on rosiglitazone by the US Food and Drug Administration J Woodcock, JM Sharfstein, M Hamburg New England Journal of Medicine 363 (16), 1489-1491, 2010 | 189 | 2010 |
| Over the counter but no longer under the radar—pediatric cough and cold medications JM Sharfstein, M North, JR Serwint New England Journal of Medicine 357 (23), 2321-2324, 2007 | 179 | 2007 |
| Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA SB Omer, RM Benjamin, NT Brewer, AM Buttenheim, T Callaghan, ... The Lancet 398 (10317), 2186-2192, 2021 | 152 | 2021 |
| Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system BK Madras, NJ Ahmad, J Wen, JS Sharfstein NAM perspectives 2020, 2020 | 149 | 2020 |
| Maryland's all-payer approach to delivery-system reform R Rajkumar, A Patel, K Murphy, JM Colmers, JD Blum, PH Conway, ... The New England journal of medicine 370 (6), 493-495, 2014 | 114 | 2014 |
| Attacks on public health officials during COVID-19 MM Mello, JA Greene, JM Sharfstein Jama 324 (8), 741-742, 2020 | 98 | 2020 |
| The urgency and challenge of opening K-12 schools in the fall of 2020 JM Sharfstein, CC Morphew Jama 324 (2), 133-134, 2020 | 92 | 2020 |
| Achieving health equity by design WF Wong, TA LaVeist, JM Sharfstein Jama 313 (14), 1417-1418, 2015 | 90 | 2015 |
| The FDA as a public health agency MA Hamburg, JM Sharfstein New England Journal of Medicine 360 (24), 2493-2495, 2009 | 89 | 2009 |
| Transforming Mental Health And Addiction Services: Commentary describes steps to improve outcomes for people with mental illness and addiction in the United States. M Alegría, RG Frank, HB Hansen, JM Sharfstein, RS Shim, M Tierney Health Affairs 40 (2), 226-234, 2021 | 77 | 2021 |
| Tobacco product regulation—a public health approach L Deyton, J Sharfstein, M Hamburg New England Journal of Medicine 362 (19), 1753-1756, 2010 | 77 | 2010 |
| A public health response to emerging technology: expansion of the Massachusetts newborn screening program. K Atkinson, B Zuckerman, JM Sharfstein, D Levin, RJ Blatt, HK Koh Public health reports 116 (2), 122, 2001 | 77 | 2001 |
| Is child health at risk while families wait for housing vouchers? J Sharfstein, M Sandel, R Kahn, H Bauchner American Journal of Public Health 91 (8), 1191-1192, 2001 | 76 | 2001 |
| The development of COVID-19 vaccines: safeguards needed N Lurie, JM Sharfstein, JL Goodman Jama 324 (5), 439-440, 2020 | 75 | 2020 |
| Uncoupling vaccination from politics: a call to action JM Sharfstein, T Callaghan, RM Carpiano, SK Sgaier, NT Brewer, ... The Lancet 398 (10307), 1211-1212, 2021 | 72 | 2021 |
Michael chernewProfessor of health care policy, Harvard medical school在 hcp.med.harvard.edu 的电子邮件经过验证
